title: Immunoconjugates of Pseudomonas exotoxin A: evaluation in mice, monkeys, and man.
abstract: Immunotoxins of PE were constructed with stable thioether linkages using two monoclonal antibodies to ovarian cancer, OVB-3 and NR-LU-10. Antigens recognized by both antibodies have limited normal tissue distribution and are expressed on virtually all ovarian cancers. Both antibodies form highly potent conjugates (ID50 = 100 pg/ml) with high selectivity (greater than or equal to 4 logs) and can eliminate greater than or equal to 5 logs of tumor cells in vitro. The conjugates have been evaluated for efficacy in both ovarian and colon carcinoma ascites xenografts. In the ovarian model, the conjugates produce an increase in life span (ILS) of 200 to 300 with some cures against established but low tumor burden ascites. Increasing the tumor burden decreases efficacy and duration of responses. A lower ILS of 150 to 200 is achieved in the more aggressive colon model. However, the combination of immunotoxin with chemotherapy, which is ineffective on its own, demonstrated enhanced activity (ILS = 300). Toxicity of the conjugates is hepatic and easily monitored by liver function tests (LDH). Antitoxin responses are highly variable, but typically have a rapid onset and appear to be predicted by preexisting levels. Pilot clinical evaluation in ovarian cancer (intraperitoneal) is ongoing.
authors.affiliation: NeoRx Corporation, Bothell, WA 98021-4406.
authors.forename: A C
authors.initials: AC
authors.lastname: Morgan
authors.forename: R
authors.initials: R
authors.lastname: Manger
authors.forename: J W
authors.initials: JW
authors.lastname: Pearson
authors.forename: D
authors.initials: D
authors.lastname: Longo
authors.forename: P
authors.initials: P
authors.lastname: Abrams
authors.forename: G
authors.initials: G
authors.lastname: Sivam
authors.forename: M
authors.initials: M
authors.lastname: Bjorn
mesh_terms: D036002:ADP Ribose Transferases; D000818:Animals; D001427:Bacterial Toxins / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D001682:Biological Availability; D005098:Exotoxins / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D000922:Immunotoxins / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D008252:Macaca fascicularis; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000628:therapy; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
chemical_list: D036002:ADP Ribose Transferases; D001427:Bacterial Toxins; D005098:Exotoxins; D000922:Immunotoxins; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A